Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.

Counseling and predictive testing are now available for the recently isolated BRCA1 and BRCA2 breast cancer susceptibility genes. We examined the societal costs of providing this counseling and testing to women at risk of having a breast cancer susceptibility mutation. Genetic counselors in a research program prospectively monitored the time necessary to provide counseling and results disclosure. A time-motion study was used to determine time spent on phone calls, preparation, and documentation for counseling. Study participants were surveyed to determine travel time and need for dependent care during counseling. The test cost was calculated using the charge for full BRCA1/2 gene sequencing (Myriad Genetics, Inc.) multiplied by a Medicare-based cost-to-charge ratio. Counselors spent an average of 4.2 h providing genetic counseling for women at risk of having a susceptibility mutation. Genetic counseling without testing cost on average $213, whereas counseling, testing, and disclosure of results totaled $2057. A brief physician-based counseling instead of genetic counselor-based counseling would produce only small reductions in total costs. Providing counseling and testing to the study population averaged $8034 per mutation found. The cost of testing and counseling exceeded $2000. The counseling portion of the cost comprised only 16% of the total cost, with the remainder representing costs associated with testing; thus, alternatives to full genetic counseling that shorten counseling time are unlikely to have a large impact on the overall cost of counseling and testing. The cost of detecting a mutation within a population of women is highly dependent on the prevalence of the mutation in the population.

[1]  J. Garber,et al.  Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. , 2000, JAMA.

[2]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[3]  M. Cho,et al.  Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. , 1999, American journal of medical genetics.

[4]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[5]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[6]  A. Mes-Masson,et al.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. , 1998, American journal of human genetics.

[7]  D. Berry,et al.  Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[9]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. King,et al.  Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. , 1998, JAMA.

[11]  J. Thompson,et al.  BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. , 1998, JAMA.

[12]  A. Neugut,et al.  Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[14]  B. Rimer,et al.  Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[16]  W. Neufeld-Kaiser,et al.  Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. , 1997, JAMA.

[17]  H. Lynch,et al.  Cancer risk assessment in a hereditary cancer prevention clinic and its first year's experience , 1997 .

[18]  K M Kuntz,et al.  Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. , 1997, The New England journal of medicine.

[19]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[20]  B. Wilfond,et al.  Genetic Testing for Susceptibility to Adult-Onset Cancer: The Process and Content of Informed Consent , 1997 .

[21]  J. Eyfjörd,et al.  Study of a single BRCA2 mutation with high carrier frequency in a small population. , 1997, American journal of human genetics.

[22]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[23]  G. Petersen,et al.  The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. , 1997, The New England journal of medicine.

[24]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[25]  B. Rimer,et al.  Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. , 1997, American journal of medical genetics.

[26]  Should we test women for inherited susceptibility to breast cancer? what do NC primary care physicians think. , 1997, North Carolina medical journal.

[27]  J. E. Nash,et al.  Psychological responses to BRCA1 mutation testing: preliminary findings. , 1997, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[28]  A. Ganguly,et al.  Detection of mutations in multi‐exon genes: Comparison of conformation sensitive gel electrophoresis and sequencing strategies with respect to cost and time for finding mutations , 1997, Human mutation.

[29]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[30]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[31]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[32]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[33]  W J Hall,et al.  Women's receptivity to testing for a genetic susceptibility to breast cancer. , 1995, American journal of public health.

[34]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[35]  B. Rimer,et al.  Effects of individualized breast cancer risk counseling: a randomized trial. , 1995, Journal of the National Cancer Institute.

[36]  M. Stefanek Bilateral prophylactic mastectomy: issues and concerns. , 1995, Journal of the National Cancer Institute. Monographs.

[37]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[38]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[39]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[40]  M. Thun,et al.  Family history, age, and risk of fatal breast cancer. , 1993, American journal of epidemiology.

[41]  J. Manson,et al.  Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. , 1993, JAMA.

[42]  P. Engstrom,et al.  Mammography adherence and psychological distress among women at risk for breast cancer. , 1993, Journal of the National Cancer Institute.

[43]  J. Holland,et al.  Psychological distress and surveillance behaviors of women with a family history of breast cancer. , 1992, Journal of the National Cancer Institute.